ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1009

Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis

Amelie Jule1, Maria Taylor2, Kacie Hoyt3, Kevin Wei4, Maria Gutierrez-Arcelus1, Siobhan Case1, Mia Chandler1, Margaret Chang2, Ezra Cohen1, Fatma Dedeoglu1, Olha Halyabar1, Jonathan Hausmann5, Melissa Hazen1, Erin Janssen1, Jeffrey Lo2, Mindy Lo1, Esra Meidan2, Jordan Roberts1, Mary Beth Son1, Robert Sundel2, Pui Lee6, Talal Chatila1, Peter Nigrovic1, Deepak Rao4 and Lauren Henderson7, 1Boston Children's Hospital, Boston, MA, 2Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 3Virginia Tech Carilion School of Medicine, Roanoke, VA, 4Brigham and Women's Hospital, Boston, MA, 5Beth Israel Deaconess Medical Center, Boston, MA, 6Boston Children's Hospital, Newton, MA, 7Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Juvenile idiopathic arthritis, Pediatric rheumatology, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Pediatric Rheumatology – Basic Science Poster (1007–1013)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement (< 5 joints) in the first 6 months of disease. A subgroup of patients presents with distinct clinical features, including early age at disease onset (< 6 years), female sex, increased risk for uveitis and antinuclear antibody (ANA) positivity. The biological processes that drive clustering of these clinical features in ANA+ oligoarthritis are not understood. The presence of autoantibodies in this oligo JIA subgroup suggests a role for abnormal B cell responses. To better understand interactions between T and B cells in oligo JIA, we characterized CD4+ T cells with a B cell-helper T cell profile in ANA+ and ANA– oligo JIA.

Methods: Synovial fluid (SF) and, where possible, paired peripheral blood (PB) samples were collected from oligo JIA patients, defined by ILAR criteria. PB was obtained from healthy controls (HC). PB and SF mononuclear cells were evaluated with flow cytometry. T effector (CD4+CD25–, Teff) and T regulatory (CD4+CD25+CD127lo) cells were sorted from the SF of 2 patients (one ANA+ and one ANA–), stained with hashing antibodies, pooled together in equal ratio, and processed for single-cell RNA sequencing (scRNA-seq) coupled with T cell receptor (TCR) repertoire using 10X. Transcriptomic data were analyzed in R using Seurat v3.1.5.

Results: 14 oligo JIA patients and 10 controls were studied. T follicular helper cells (CD4+PD-1hiCXCR5+, Tfh) are found in secondary lymphoid organs and express factors (PD1, ICOS, IL-21, CXCL13) promoting B cell maturation and antibody production. Compared to the PB of controls and patients, Tfh cells were not significantly enriched in the SF of ANA+ or ANA– oligo JIA. In peripheral tissues, B cells are driven to mature and generate autoantibodies by T peripheral helper cells (CD4+PD-1hiCXCR5–, Tph). Flow cytometry studies showed a significant enrichment of Tph cells in the SF of oligo JIA patients. ANA+ patients had the highest proportion of Tph cells, with 50.8% ± 5.5 (mean ± SEM) of Tph among total CD4+ T cells, compared to 32.5% ± 3.4 in ANA– patients. In contrast, Tph cells were rare in the PB of patients and controls (< 6.5% of CD4+ T cells). Tph cells in SF expressed markers of B cell-helper T cells, including ICOS and the B cell chemoattractant CXCL13. scRNA-seq studies of SF CD4+ T cells revealed 2 clusters with Tph features, including cells co-expressing high levels of PDCD1 (gene encoding PD1) and CXCL13 alongside transcription factors previously identified in Tph cells (MAF and BATF). A greater proportion of Teff cells from the ANA+ patient (48%) compared to the ANA– patient (25%) was found in Tph clusters. TCR repertoire analysis showed that clonally expanded T cells (with at least 3 clonal TCR copies) concentrated in Tph clusters and were mostly observed in the ANA+ patient.

Conclusion: Our results show that T cells with features of B cell-helper T cells preferentially accumulate in the joints of children with ANA+ oligo JIA. These results suggest that beyond the clinical features that characterize early-onset, ANA+ oligo JIA, disordered T cell-mediated help to B cells may further define this patient subset. Further studies are needed to delineate the functionality of Tph cells in oligo JIA.

T peripheral helper (Tph) cells are enriched in the synovial fluid (SF) of ANA+ oligo JIA. A) Representative flow cytometry dot plots gated on live CD3+CD4+ T cells. Frequencies of Tph cells (PD1hi, CXCR5-) and of the B-cell chemoattractant CXCL13 in oligo JIA SF are highlighted in red. B) Mean frequency ± SEM of CD3+CD4+ T cells expressing the corresponding markers. Statistical testing: ANOVA with correction for multiple comparisons; p-value < 0.05 *; < 0.01 **, < 0.001 ***, < 0.0001 **** (for readability, not all significant comparisons are shown).

Single-cell RNA sequencing of SF CD4+ T cells reveal clonally expanded cells with features of Tph cells in ANA+ oligo JIA. Sorted Tregs (CD4+CD25+CD127lo) and Teffs (CD4+CD25-) from the SF of 2 oligo JIA patients were studied with 10X. A) Uniform manifold approximation and projection (UMAP) of global dataset (both subjects, 6190 cells), color-coded by cluster. Clusters 6 & 7 contain Tph cells. B) UMAP of global dataset, showing gene expression levels of key Tph cell markers. C) UMAP of dataset, split by patient. The percent of T effector cells found in each Tph cluster for each patient is shown. D) UMAP projection, split by patient, highlighting T cell clones with strictly more than 3 copies across the dataset (expanded clones). A clone is defined by its paired TCRα and TCRβ chain.


Disclosures: A. Jule, None; M. Taylor, None; K. Hoyt, None; K. Wei, Mestag, 2; M. Gutierrez-Arcelus, None; S. Case, None; M. Chandler, None; M. Chang, None; E. Cohen, None; F. Dedeoglu, Novartis, 2, UptoDate, 9; O. Halyabar, None; J. Hausmann, Novartis, 2, Biogen, 2, Pfizer, 2; M. Hazen, None; E. Janssen, None; J. Lo, None; M. Lo, None; E. Meidan, None; J. Roberts, None; M. Son, CARRA, 5, UpToDate, 5; R. Sundel, None; P. Lee, None; T. Chatila, None; P. Nigrovic, AbbVie, 5, Bristol-Myers Squibb, 5, Novarits, 5, Pfizer, 5, Sobi, 5, CARRA, 5, UpToDate, 9; D. Rao, Janssen, 5, 6, Bristol-Myers Squibb, 1, 5, Scipher Medicine, 2, Pfizer, 6, Merck, 6; L. Henderson, None.

To cite this abstract in AMA style:

Jule A, Taylor M, Hoyt K, Wei K, Gutierrez-Arcelus M, Case S, Chandler M, Chang M, Cohen E, Dedeoglu F, Halyabar O, Hausmann J, Hazen M, Janssen E, Lo J, Lo M, Meidan E, Roberts J, Son M, Sundel R, Lee P, Chatila T, Nigrovic P, Rao D, Henderson L. Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/expanded-b-cell-helper-t-cells-in-ana-oligoarticular-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expanded-b-cell-helper-t-cells-in-ana-oligoarticular-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology